Synthesis and Cytotoxic Activity Study of Novel 2-(Aryldiazenyl)-3-methyl-1H-benzo[g]indole Derivatives
Abstract
:1. Introduction
2. Results and Discussion
2.1. Synthesis of Benzo[g]indoles
2.2. Cytotoxic Activity Screening
3. Materials and Methods
3.1. Chemistry
3.1.1. General Procedure for the Preparation of the 1-arylhydrazono-1-chloroacetone (1a–f)
3.1.2. General Procedure for the Preparation of 1-(naphthylamino)-1-(arylhydrazono)-2-propanone (2a–f)
3.1.3. General Procedure for the Synthesis of 2-(Aryldiazenyl)-3-methyl-1H-benzo[g]indoles (3a–f)
3.2. In Vitro Cytotoxicity Assay
4. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- Li, L.; Qian, Y.; Sun, L.; Han, F.Y.; Zhang, R.; Wang, P.Y.; Xu, Z.P. Albumin-stabilized layered double hydroxide nanoparticles synergized combination chemotherapy for colorectal cancer treatment. Nanomed. Nanotechnol. Biol. Med. 2021, 34, 102369. [Google Scholar] [CrossRef]
- Calabresi, P.; Chabner, B.A. Goodmann & Gillman’s Pharmacological Basis of Therapeutics, 12th ed.; McGraw-Hill: New York, NY, USA, 2011. [Google Scholar]
- Borthakur, M.; Gogoi, S.; Gogoi, J.; Boruah, R.C. Lewis acid catalyzed rapid synthesis of 5-hydroxy-benzo [g] indole scaffolds by a modified Nenitzescu reaction. Tetrahedron Lett. 2010, 51, 5160–5163. [Google Scholar] [CrossRef]
- Moghadam, E.S.; Hamel, E.; Shahsavari, Z.; Amini, M. Synthesis and anti-breast cancer activity of novel indibulin related diarylpyrrole derivatives. DARU J. Pharm. Sci. 2019, 27, 179–189. [Google Scholar] [CrossRef]
- Gribble, G.W. Recent developments in indole ring synthesis—Methodology and applications. J. Chem. Soc. Perkin Trans. 2000, 7, 1045–1075. [Google Scholar] [CrossRef]
- Gribble, G.W. Novel chemistry of indole in the synthesis of heterocycles. Pure Appl. Chem. 2003, 75, 1417–1432. [Google Scholar] [CrossRef] [Green Version]
- Agarwal, S.; Cammerer, S.; Filali, S.; Frohner, W.; Knoll, J.; Krahl, M.P.; Reddy, K.R.; Knolker, H.J. Novel routes to pyrroles, indoles and carbazoles-applications in natural product synthesis. Curr. Org. Chem. 2005, 9, 1601–1614. [Google Scholar] [CrossRef]
- Humphrey, G.R.; Kuethe, J.T. Practical methodologies for the synthesis of indoles. Chem. Rev. 2006, 106, 2875–2911. [Google Scholar] [CrossRef]
- Inman, M.; Moody, C.J. Indole synthesis–something old, something new. Chem. Sci. 2013, 4, 29–41. [Google Scholar] [CrossRef]
- Adams, D.; Bénardeau, A.; Bickerdike, M.J.; Bentley, J.M.; Bissantz, C.; Bourson, A.; Cliffe, I.A.; Hebeisen, P.; Kennett, G.A.; Knight, A.R.; et al. 5-HT2C receptor agonists for the treatment of obesity. Biological and chemical adventures. CHIMIA Int. J. Chem. 2004, 58, 613–620. [Google Scholar] [CrossRef]
- Nishino, H.; Murakoshi, M.; Mou, X.Y.; Wada, S.; Masuda, M.; Ohsaka, Y.; Satomi, Y.; Jinno, K. Cancer prevention by phytochemicals. Oncology 2005, 69, 38–40. [Google Scholar] [CrossRef] [PubMed]
- Bruno, F.; Errico, S.; Pace, S.; Nawrozkij, M.B.; Mkrtchyan, A.S.; Guida, F.; Maisto, R.; Olgaç, A.; D’Amico, M.; Maione, S.; et al. Structural insight into the optimization of ethyl 5-hydroxybenzo [g] indol-3-carboxylates and their bioisosteric analogues as 5-LO/m-PGES-1 dual inhibitors able to suppress inflammation. Eur. J. Med. Chem. 2018, 155, 946–960. [Google Scholar] [CrossRef] [PubMed]
- Faust, R.; Garratt, P.J.; Jones, R.; Yeh, L.K.; Tsotinis, A.; Panoussopoulou, M.; Calogeropoulou, T.; Teh, M.T.; Sugden, D. Mapping the melatonin receptor. 6. Melatonin agonists and antagonists derived from 6 H-isoindolo [2,1-a] indoles, 5, 6-dihydroindolo [2,1-a] isoquinolines, and 6,7-dihydro-5 H-benzo [c] azepino [2,1-a] indoles. J. Med. Chem. 2000, 43, 1050–1061. [Google Scholar] [CrossRef] [PubMed]
- Jiang, F.; Wei, Q.; Li, H.; Li, H.; Cui, Y.; Ma, Y.; Chen, H.; Cao, P.; Lu, T.; Chen, Y. Discovery of novel small molecule induced selective degradation of the bromodomain and extra-terminal (BET) bromodomain protein BRD4 and BRD2 with cellular potencies. Bioorg. Med. Chem. 2020, 28, 115181. [Google Scholar] [CrossRef]
- Yasuda, D.; Yuasa, A.; Obata, R.; Nakajima, M.; Takahashi, K.; Ohe, T.; Ichimura, Y.; Komatsu, M.; Yamamoto, M.; Imamura, R.; et al. Discovery of benzo [g] indoles as a novel class of non-covalent Keap1-Nrf2 protein-protein interaction inhibitor. Bioorg. Med. Chem. Lett. 2017, 27, 5006–5009. [Google Scholar] [CrossRef]
- Peduto, A.; Krauth, V.; Collarile, S.; Dehm, F.; Ambruosi, M.; Belardo, C.; Guida, F.; Massa, A.; Esposito, V.; Maione, S.; et al. Exploring the role of chloro and methyl substitutions in 2-phenylthiomethyl-benzoindole derivatives for 5-LOX enzyme inhibition. Eur. J. Med. Chem. 2016, 108, 466–475. [Google Scholar] [CrossRef]
- Dias, F.R.; Guerra, F.S.; Lima, F.A.; de Castro, Y.K.; Ferreira, V.F.; Campos, V.R.; Fernandes, P.D.; Cunha, A.C. Synthesis and Biological Evaluation of Benzo [f] indole-4,9-diones N-Linked to Carbohydrate Chains as New Type of Antitumor Agents. J. Braz. Chem. Soc. 2021, 32, 476–489. [Google Scholar] [CrossRef]
- Pappa, G.; Lichtenberg, M.; Iori, R.; Barillari, J.; Bartsch, H.; Gerhäuser, C. Comparison of growth inhibition profiles and mechanisms of apoptosis induction in human colon cancer cell lines by isothiocyanates and indoles from Brassicaceae. Mutat. Res. Fundam. Mol. Mech. Mutagenes. 2006, 599, 76–87. [Google Scholar] [CrossRef]
- Koeberle, A.; Haberl, E.M.; Rossi, A.; Pergola, C.; Dehm, F.; Northoff, H.; Troschuetz, R.; Sautebin, L.; Werz, O. Discovery of benzo [g] indol-3-carboxylates as potent inhibitors of microsomal prostaglandin E2 synthase-1. Bioorg. Med. Chem. 2009, 17, 7924–7932. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Gach, K.; Modranka, J.; Szymański, J.; Pomorska, D.; Krajewska, U.; Mirowski, M.; Janecki, T.; Janecka, A. Anticancer properties of new synthetic hybrid molecules combining naphtho [2,3-b] furan-4, 9-dione or benzo [f] indole-4,9-dione motif with phosphonate subunit. Eur. J. Med. Chem. 2016, 120, 51–63. [Google Scholar] [CrossRef] [PubMed]
- Wurm, G.; Baumann, J.; Geres, U.; Schmidt, H. Lipophilic naphthols and 1,4-naphthoquinones as inhibitors of prostaglandin synthesis. 6. Study of 1,4-naphthoquinones. Arzneim. Forsch. 1984, 34, 652–658. [Google Scholar]
- Singh, W.M.; Dash, B.C. Synthesis of some new Schiff bases containing thiazole and oxazole nuclei and their fungicidal activity. Pesticides 1988, 22, 33–37. [Google Scholar]
- El-masry, A.H.; Fahmy, H.H.; Ali Abdelwahed, S.H. Synthesis and antimicrobial activity of some new benzimidazole derivatives. Molecules 2000, 5, 1429–1438. [Google Scholar] [CrossRef]
- Gomha, S.M.; Salah, T.A.; Abdelhamid, A.O. Synthesis, characterization, and pharmacological evaluation of some novel thiadiazoles and thiazoles incorporating pyrazole moiety as anticancer agents. Mon. Chem. Chem. Mon. 2015, 146, 149–158. [Google Scholar] [CrossRef]
- Tevyashova, A.N.; Olsufyeva, E.N.; Turchin, K.F.; Balzarini, J.; Bykov, E.E.; Dezhenkova, L.G.; Shtil, A.A.; Preobrazhenskaya, M.N. Reaction of the antitumor antibiotic olivomycin I with aryl diazonium salts. Synthesis, cytotoxic and antiretroviral potency of 5-aryldiazenyl-6-O-deglycosyl derivatives of olivomycin I. Bioorg. Med. Chem. 2009, 17, 4961–4967. [Google Scholar] [CrossRef]
- Dougan, S.J.; Melchart, M.; Habtemariam, A.; Parsons, S.; Sadler, P.J. Phenylazo-pyridine and phenylazo-pyrazole chlorido ruthenium (II) arene complexes: Arene loss, aquation, and cancer cell cytotoxicity. Inorg. Chem. 2006, 45, 10882–10894. [Google Scholar] [CrossRef]
- Shoemaker, R.H. The NCI60 human tumour cell line anticancer drug screen. Nat. Rev. Cancer 2006, 6, 813–823. [Google Scholar] [CrossRef]
- Pinna, G.A.; Loriga, G.; Murineddu, G.; Grella, G.; Mura, M.; Vargiu, L.; Murgioni, C.; La Colla, P. Synthesis and anti-HIV-1 activity of new delavirdine analogues carrying arylpyrrole moieties. Chem. Pharm. Bull. 2001, 49, 1406–1411. [Google Scholar] [CrossRef] [Green Version]
- Chacón-García, L.; Martínez, R. Synthesis and in vitro cytotoxic activity of pyrrolo [2,3-e] indole derivatives and a dihydro benzoindole analogue. Eur. J. Med. Chem. 2002, 37, 261–266. [Google Scholar] [CrossRef]
- Oslund, R.C.; Cermak, N.; Gelb, M.H. Highly specific and broadly potent inhibitors of mammalian secreted phospholipases A2. J. Med. Chem. 2008, 51, 4708–4714. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Moghadam, E.S.; Tehrani, M.H.; Csuk, R.; Fischer, L.; Faramarzi, M.A.; Rashidi, A.; Javadi, I.; Amini, M. 2,4-Disubstituted Quinazoline Derivatives Act as Inducers of Tubulin Polymerization: Synthesis and Cytotoxicity. Anti-Cancer Agents Med. Chem. 2019, 19, 1048–1057. [Google Scholar] [CrossRef] [PubMed]
- Hong, B.C.; Jiang, Y.F.; Chang, Y.L.; Lee, S.J. Synthesis and Cytotoxicity Studies of Cyclohepta [b] indoles, Benzo [6,7] Cyclohepta [1,2-b] Indoles, Indeno [1,2-b] Indoles, and Benzo [a] Carbazoles. J. Chin. Chem. Soc. 2006, 53, 647–662. [Google Scholar] [CrossRef]
Panel/Cell Line | Growth Percent | |||
---|---|---|---|---|
2a | 2c | 3a | 3c | |
Non-small cell lung cancer | ||||
A549/ATCC | 69.44 | 84.26 | 92.54 | 80.09 |
EKVX | 76.03 | 78.76 | 73.09 | 74.93 |
HOP-62 | 81.34 | 51.51 | 29.60 | 25.91 |
HOP-92 | 33.21 | 35.72 | 60.21 | 44.83 |
NCI-H226 | 99.51 | 92.05 | 99.78 | 100.75 |
NCI-H23 | 73.65 | 64.91 | 84.97 | 78.89 |
NCI-H322M | 91.49 | 105.11 | 97.36 | 68.40 |
NCI-H460 | 75.61 | 94.59 | 94.86 | 72.23 |
NCI-H522 | 75.81 | 54.91 | 91.34 | 73.86 |
Colon cancer | ||||
COLO 205 | 14.30 | 99.52 | 94.11 | 103.74 |
HCC 2998 | 96.18 | 104.22 | 112.55 | 82.06 |
HCT-116 | 57.79 | 31.85 | 81.24 | 36.33 |
HCT-15 | 83.87 | 63.16 | 93.35 | 97.05 |
HT29 | 90.12 | 71.13 | 95.74 | 63.32 |
KM12 | 73.78 | 72.32 | 94.26 | 55.31 |
SW-620 | 86.13 | 83.69 | 89.85 | 92.36 |
Breast cancer | ||||
BT-549 | 103.70 | 89.37 | 106.49 | 85.34 |
HS 578T | 93.72 | 86.11 | 99.28 | 47.64 |
MCF7 | 82.09 | 62.01 | 75.06 | 73.52 |
MDA-MB231/ATCC | 67.35 | 18.85 | 75.32 | 51.11 |
MDA-MB-435 | 73.89 | 89.88 | 117.26 | 79.44 |
NCI/ADR-RES | 79.52 | 53.56 | 97.52 | 57.70 |
T-47D | 77.39 | 57.95 | 57.02 | 65.60 |
Ovarian cancer | ||||
IGROV1 | 46.54 | 28.70 | 55.11 | n.d |
OVCAR-3 | 80.17 | 70.33 | 113.38 | 83.26 |
OVCAR-4 | 83.45 | 58.02 | 76.65 | 58.59 |
OVCAR-5 | 87.30 | 101.63 | 74.65 | 91.62 |
OVCAR-8 | 80.46 | 56.55 | 85.78 | 42.45 |
SK-OV-3 | 91.80 | 86.27 | 56.87 | 56.47 |
Leukemia | ||||
CCRF-CEM | n.d | n.d | 55.11 | n.d |
HL-60 (TB) | 98.62 | 63.94 | 113.38 | 65.44 |
K-562 | 81.97 | 61.96 | 76.40 | 52.58 |
MOLT-4 | 70.05 | 30.61 | 74.65 | 68.43 |
RPMI-8226 | 101.28 | 55.40 | 85.78 | 41.72 |
SR | 52.89 | 44.50 | 56.87 | 42.01 |
Renal cancer | ||||
786-0 | 92.49 | 42.69 | 96.80 | 33.52 |
A498 | 79.07 | 86.05 | 102.61 | 104.03 |
ACHN | 79.25 | 84.86 | 91.60 | 59.22 |
CAKI-1 | 73.31 | 85.31 | 92.56 | 65.21 |
RXF-393 | 82.22 | 67.14 | 91.82 | 56.38 |
SN12C | 82.55 | 86.62 | 125.05 | 66.78 |
TK-10 | 118.78 | 133.33 | 121.64 | 51.66 |
UO-31 | 50.27 | 41.83 | 71.11 | 30.48 |
Melanoma | ||||
LOX IMVI | 82.55 | 19.76 | 90.71 | 65.76 |
M14 | 96.72 | 81.03 | 105.14 | 88.37 |
MALME-3M | 107.30 | 88.02 | 98.42 | 54.84 |
SK-MEL-2 | 96.85 | 79.25 | 106.50 | 104.37 |
SKMEL-28 | 119.81 | 114.44 | 107.48 | 121.72 |
XKMEL-5 | 88.71 | 89.46 | 91.32 | 93.18 |
UACC-257 | 84.78 | 80.16 | 98.19 | 94.79 |
UACC-62 | 78.97 | 76.16 | 89.78 | 72.57 |
Prostate cancer | ||||
DU-145 | 107.24 | 94.77 | 98.36 | 66.38 |
PC-3 | 108.27 | 49.85 | 66.82 | 4.60 |
CNS cancer | ||||
SF-268 | 95.30 | 79.49 | 92.41 | 57.88 |
SF-295 | 49.59 | 87.95 | 89.78 | 82.65 |
SF-539 | 87.43 | 84.04 | 82.23 | 72.03 |
SNB-19 | 86.64 | 87.85 | 102.38 | 82.38 |
SNB-75 | 77.18 | 94.99 | 89.21 | 65.17 |
U251 | 90.64 | 74.01 | 100.46 | 44.23 |
Mean | 81.84 | 72.63 | 89.46 | 65.99 |
2c | 3c | |||||||
---|---|---|---|---|---|---|---|---|
Cell Line | GP | GI50 | TGI | LC50 | GP | GI50 | TGI | LC50 |
Leukemia | ||||||||
CCRF-CEM | 13 | 8.2 | 50 | 50 | 5 | 0.486 | 25 | 25 |
HL−60(TB) | −18 | 3.9 | 26.3 | 50 | −3 | 0.56 | 15.5 | 25 |
K−562 | 12.8 | 50 | 50 | 50 | 10 | 0.528 | 25 | 25 |
MOLT−4 | −16 | 2.3 | 21.4 | 50 | −42 | 0.373 | 1 | 25 |
RPMI−8226 | 24 | 3.91 | 50 | 50 | −6 | 0.382 | 4.13 | 25 |
SR | 42 | 23.3 | 50 | 50 | −28 | 0.32 | 1.29 | 25 |
Non-small cell lung cancer | ||||||||
A549/ATCC | 43 | 35.2 | 50 | 50 | 29 | 1.81 | 25 | 25 |
EKVX | 40 | 29.4 | 50 | 50 | 21 | 0.803 | 25 | 25 |
HOP−62 | 63 | 50 | 50 | 50 | 26 | 1.95 | 25 | 25 |
HOP−92 | 49 | 45.8 | 50 | 50 | 25 | 0.973 | 25 | 25 |
NCI-H226 | 3 | 3.3 | 50 | 50 | 37 | 1.67 | 25 | 25 |
NCI-H23 | 24 | 12.5 | 50 | 50 | 36 | 1.92 | 25 | 25 |
NCI-H322M | 31 | 19 | 50 | 50 | 67 | 25 | 25 | 25 |
NCI-H460 | 24 | 19.5 | 50 | 50 | 17 | 1.21 | 25 | 25 |
Colon Cancer | ||||||||
COLO 205 | 72 | 50 | 50 | 50 | 21 | 1.12 | 25 | 25 |
HCC−2998 | 80 | 50 | 50 | 50 | 70 | 25 | 25 | 25 |
HCT−116 | 8 | 5.6 | 50 | 50 | 25 | 0.989 | 25 | 25 |
HCT−15 | 42 | 12.2 | 50 | 50 | 29 | 0.711 | 25 | 25 |
HT29 | 6 | 12.6 | 50 | 50 | 12 | 0.727 | 25 | 25 |
KM12 | 12 | 11.3 | 50 | 50 | 24 | 1.63 | 25 | 25 |
SW−620 | 32 | 2.03 | 50 | 50 | 25 | 1.89 | 25 | 25 |
CNS cancer | ||||||||
SF−26836 | 18.8 | 50 | 50 | 50 | 40 | 2.35 | 25 | 25 |
SF−295−3 | 8.7 | 45.9 | 50 | 50 | 4 | 0.997 | 25 | 25 |
SF−53926 | 15.2 | 50 | 50 | 50 | 36 | 1.16 | 25 | 25 |
SNB−19 | 56 | 50 | 50 | 50 | 44 | 2.75 | 25 | 25 |
SNB−75 | 34 | 17.8 | 50 | 50 | 10 | 0.722 | 25 | 25 |
U25136 | 26 | 50 | 50 | 50 | 23 | 0.936 | 25 | 25 |
Melanoma | ||||||||
LOX IMVI | 2 | 1.86 | 50 | 50 | 6 | 0.681 | 25 | 25 |
MALME−3M | −3 | 5.44 | 43.9 | 50 | 20 | 0.662 | 25 | 25 |
MDA-MB−4 | 35 | 9 | 14.2 | 50 | 18 | 1.1 | 25 | 25 |
SK-MEL−2 | 37 | 17.5 | 50 | 50 | 21 | 1.15 | 25 | 25 |
SK-MEL−28 | 65 | 50 | 50 | 50 | 6 | 0.689 | 25 | 25 |
SK-MEL−5 | 40 | 28.2 | 50 | 50 | −46 | 0.429 | 1.17 | 25 |
UACC−257 | 38 | 27.2 | 50 | 50 | 17 | 1.44 | 25 | 25 |
UACC−62 | 44 | 31.2 | 50 | 50 | 22 | 1.28 | 25 | 25 |
Ovarian | ||||||||
OVCAR−3 | 5 | 9.12 | 50 | 50 | 27 | 1.4 | 25 | 25 |
OVCAR−4 | 18 | 4.73 | 50 | 50 | 20 | 0.973 | 25 | 25 |
OVCAR−5 | 124 | 50 | 50 | 50 | 86 | 25 | 25 | 25 |
OVCAR−8 | 31 | 16.5 | 50 | 50 | 28 | 1.69 | 25 | 25 |
NCI/ADR-RES | 25 | 8.72 | 50 | 50 | 18 | 1.07 | 25 | 25 |
SK-OV−3 | 48 | 42.5 | 50 | 50 | 42 | 8.57 | 25 | 25 |
Renal Cancer | ||||||||
786−0 | 50 | 49.9 | 50 | 50 | 7 | 1.15 | 25 | 25 |
A498 | 23 | 15.7 | 50 | 50 | −14 | 0.605 | 22.4 | 25 |
ACHN | 40 | 26.5 | 50 | 50 | 24 | 0.997 | 25 | 25 |
CAKI−1 | 22 | 13.6 | 50 | 50 | 32 | 1.05 | 25 | 25 |
RXF 393 | 13 | 2.11 | 50 | 50 | −25 | 0.336 | 1.27 | 25 |
SN12C | 14 | 8.14 | 50 | 50 | 44 | 2.09 | 25 | 25 |
TK−10 | 46 | 44.4 | 50 | 50 | 60 | 25 | 25 | 25 |
UO−31 | 29 | 4.96 | 50 | 50 | 34 | 1.63 | 25 | 25 |
Prostate | ||||||||
PC3 | 29 | 10.2 | 50 | 50 | 14 | 0.515 | 25 | 25 |
DU−145 | 40 | 30.4 | 50 | 50 | 53 | 25 | 25 | 25 |
Breast | ||||||||
MCF7 | 4 | 6.42 | 50 | 50 | 11 | 0.704 | 25 | 25 |
MDA−231 | 10 | 3.15 | 50 | 50 | 20 | 0.94 | 25 | 25 |
HS 578T | −25 | 6.05 | 50 | 50 | −44 | 0.053 | 0.0479 | 25 |
BT−549 | 55 | 50 | 50 | 50 | 6 | 0.51 | 25 | 25 |
T−47D | 42 | 24.8 | 50 | 50 | 5 | 0.364 | 25 | 25 |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Arafeh, M.M.; Moghadam, E.S.; Adham, S.A.I.; Stoll, R.; Abdel-Jalil, R.J. Synthesis and Cytotoxic Activity Study of Novel 2-(Aryldiazenyl)-3-methyl-1H-benzo[g]indole Derivatives. Molecules 2021, 26, 4240. https://doi.org/10.3390/molecules26144240
Arafeh MM, Moghadam ES, Adham SAI, Stoll R, Abdel-Jalil RJ. Synthesis and Cytotoxic Activity Study of Novel 2-(Aryldiazenyl)-3-methyl-1H-benzo[g]indole Derivatives. Molecules. 2021; 26(14):4240. https://doi.org/10.3390/molecules26144240
Chicago/Turabian StyleArafeh, Manar M., Ebrahim Saeedian Moghadam, Sirin A. I. Adham, Raphael Stoll, and Raid J. Abdel-Jalil. 2021. "Synthesis and Cytotoxic Activity Study of Novel 2-(Aryldiazenyl)-3-methyl-1H-benzo[g]indole Derivatives" Molecules 26, no. 14: 4240. https://doi.org/10.3390/molecules26144240